Greetings from the ACTO chairperson

Greetings from the Editor-in Chief

ACTO 2026 Distinguished Speakers

---

Spotlight: Regional CGT updates

China’s Evolving Regulatory Framework for Cell and Gene Therapies: From Dual-Track Oversight to a New Legal Phase

South Korea’s Regulatory Architecture for Cell and Gene Therapies: Linking Clinical Research, Regulated Treatment, and Product Authorization

---

ACADEMIC HIGHLIGHT: ADVANCES IN IMMUNOLOGY

Reimagining Cancer Treatment: The 2026 Tang Prize Laureates in Biopharmaceutical Science

T Cell-based Therapy: Milestones, Prospects and Market Perspective

From First Responders to Tumor Accomplices: The Plasticity of Neutrophils in Cancer

CD19 and BCMA CAR-T Cell Therapy: A New Era in Autoimmune Disease Treatment

---

CGT INDUSTRY

ELIXCYTE ® (Allogeneic Mesenchymal Stem Cell): An Integrated Translational Framework Supporting Clinical Development, Mechanism of Action, and Potency Assessment

Beginning with the End in Mind, the Journey of Mesenchymal Stem/stromal Cell Therapy Product Development

China’s CAR-T and Immune Cell Therapy CDMO Landscape: Process Development, GMP Manufacturing, and Platform-Based Global Expansion

---

Special Topic

From AI Agents to Automated Cell Factories: How Artificial Intelligence Is Reshaping Drug Development, Digital Biology, and Cell Therapy

AMCHEPRY®: The First iPSC-Derived Cell Therapy Marks a New Era of Regenerative Medicine for Parkinson’s Disease

From Pluripotency to Patients: Current Progress in iPSC-Based Clinical Trials

Trends of Gene Therapy Clinical Trials